Spebrutinib

Drug Profile

Spebrutinib

Alternative Names: AVL-292; CC-292

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Avila Therapeutics
  • Developer Celgene Corporation
  • Class Acrylamides; Aniline compounds; Antineoplastics; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • No development reported Cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Dec 2016 Efficacy and adverse event data from a phase Ib trial in Diffuse large B-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 11 Nov 2016 Efficacy, pharmacodyanamic and adverse event data from a phase IIa trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top